Percutaneous coronary interventions with drug eluting stents for diabetic patients

Heart

Volumn 92, Issue 3, 2006, Pages 410-419

  Seabra Gomes, Ricardo ^a  

^a Instituto do Coracao   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANGIOTENSIN II; CD11B ANTIGEN; CLOPIDOGREL; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE; PACLITAXEL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTACYCLIN; RAPAMYCIN; TICLOPIDINE; TRANSCRIPTION FACTOR; VITRONECTIN RECEPTOR;

ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INTERNAL MAMMARY ARTERY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RESTENOSIS; REVIEW; THROMBOCYTE ACTIVATION; THROMBOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY BYPASS; DIABETIC ANGIOPATHIES; HUMANS; MYOCARDIAL REVASCULARIZATION; STENTS;

EID: 33644533853     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2005.062992     Document Type: Review

References (28)

1. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis. Epidemiology, pathophysiology and management. JAMA 2002;287:2570-81. Excellent review of the pathophysiology of diabetic vascular disease.
2. Hoffman SN, TenBrook JA, Wolf MP, et al. A meta-analysis of randomised controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one- to eight-year outcomes. J Am Coll Cardiol 2003;41:1293-304.
3. Brophy JM, Belisle P, Joseph L. Evidence for use of coronary stents. A hierarchical Bayesian meta-analysis. Ann Intern Med 2003;138:777-86.
4. Gilbert J, Raboud J, Zinman B. Meta-analysis of the effect of diabetes on restenosis rates among patients receiving coronary angioplasty stenting. Diabetes Core 2004;27:990-4. This study raises the possibility that other factors besides stents can be responsible for the higher restenosis rates in diabetics.
5. Serruys PW, Ong ATL, van Herwerden LA, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease. J Am Coll Cardiol 2005;46:575-81. Long term results of an important RCT between CABG and standard stent PCI.
6. Bhatt DL, Marso SP, Lincoff M, et al. Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol 2000;35:922-8.
7. Mehilli J, Kastrati A, Schuhlen M, et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004;110:3627-35. Abciximab in diabetics can reduce restenosis and TLR.
8. Corpus RA, George PB, House JA, et al. Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention. J Am Coll Cardiol 2004;43:8-14.
9. Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus. Results from a controlled randomised study. Circulation 2005;111:2525-31.
10. Babapulle MN, Joseph L, Bélisle P, et al. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004;364:583-91.
11. Kastrati A, Dibra A, Eberle S, et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease. Meta-analysis of randomised trials. JAMA 2005;294:819-25. Recent meta-analysis of RCT with different DES.
12. Moreno R, Fernández C, Hernández, et al. Drug-eluting stent thrombosis. Results from a pooled analysis including 10 randomized studies. J Am Coll Cardiol 2005;45:954-9.
13. Ong ATL, Hoye A, Aoki J, et al. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation. J Am Coll Cardiol 2005;45:947-53.
14. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-30. Importance of stent thrombosis with DES.
15. Moussa I, Leon MB, Baim DS, et al. Impact of sirolimus-eluting stents on outcome in diabetic patients. A SIRIUS (sirolimus-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo coronary artery lesions) substudy. Circulation 2004;109:2273-8.
16. Hermiller JB, Raizner A, Cannon L, et al. Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus. The TAXUS-IV trial. J Am Coll Cardiol 2005;45:1172-9.
17. Macaya C, Garcia H, Serruys PW, et al. Sirolimus-eluting stent versus surgery and bare metal stenting in the treatment of diabetic patients with multivessel disease-a comparison between ARTS II and ARTS I. Circulation 2005;112(suppl II):II-655.
18. Ong ATL, Aoki J, van Mieghem CAG, et al. Comparison of short- (one month) and long- (twelve months) term outcomes of sirolimus- versus paclitaxel-eluting stents in 293 consecutive patients with diabetes mellitus (from the RESEARCH and T-SEARCH registries). Am J Cardiol 2005;96:358-62.
19. Sabate M, Jiménez-Quevedo P, Angiolillo DJ, et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation 2005;112:2175-83. First RCT with DES in diabetics.
20. Dibra A, Kastrati A, Mehilli J, et al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005;353:663-70. First RCT in diabetics comparing sirolimus and paclitaxel DES.
21. Costa MA, Simon DI. Molecular basis of restenosis and drug-eluting stents. Circulation 2005;111:2257-73. Very important review of the mechanisms of restenosis in the DES era.
22. Lemos PA, Mercado N, van Domburg RT, et al. Comparison of late luminal loss response pattern after sirolimus-eluting stent implantation or conventional stenting. Circulation 2004;110:3199-205.
23. Mauri L, Orav EJ, O'Malley AJ, et al. Relationship of late loss in lumen diameter to coronary restenosis in sirolimus-eluting stents. Circulation 2005;111:321-7.
24. Ellis SG, Popma JJ, Lasala JM, et al. Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation. Analysis from the TAXUS-IV trial. J Am Coll Cardiol 2005;45:1193-200.
25. Mauri L, Orav EJ, Kuntz RE. Late loss in lumen diameter and binary restenosis for drug-eluting stent comparison. Circulation 2005;111:3435-42. Excellent review of the importance of LL and binary restenosis for DES comparison.
26. Scheen AJ, Warzée F, Legrand VMG. Drug-eluting stents: meta-analysis in diabetic patients [letter]. Eur Heart J 2004;25:2167-8.
27. Prior JO, Quiñones MJ, Hernadez-Pampaloni M, et al. Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance and type 2 diabetes mellitus. Circulation 2005;111:2291-8.
28. Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. JAMA 2005;293:1501-8. Most recent review of coronary revascularisation in diabetics.